ChiCTR2300076296 版本V1.1 版本创建时间2024/03/07 20:35:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300076296 

最近更新日期:

Date of Last Refreshed on:

2023-09-28 17:47:43 

注册时间:

Date of Registration:

2023-09-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

低GI大米对2型糖尿病患者血糖控制的影响

Public title:

Effect of low GI rice on blood glucose control in patients with type 2 diabetes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

低GI大米对2型糖尿病患者血糖控制的影响

Scientific title:

Effect of low GI rice on blood glucose control in patients with type 2 diabetes

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吕亭亭 

研究负责人:

葛声 

Applicant:

Tingting Lv 

Study leader:

Sheng Ge 

申请注册联系人电话:

Applicant telephone:

+86 189 1653 5119

研究负责人电话:

Study leader's telephone:

+86 24058352

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuyuanlvting@163.com

研究负责人电子邮件:

Study leader's E-mail:

gesheng607@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市第六人民医院,上海市徐汇区

研究负责人通讯地址:

上海市第六人民医院,上海市徐汇区

Applicant address:

Shanghai 6th People's hospital ,Shanghai 200233,P. R. China

Study leader's address:

Shanghai 6th People's hospital ,Shanghai 200233,P. R. China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市第六人民医院

Applicant's institution:

Shanghai 6th People's hospital

研究负责人所在单位:

上海市第六人民医院

Affiliation of the Leader:

Shanghai 6th People's hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023-093

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市第六人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Sixth People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-04 00:00:00

伦理委员会联系人:

孙秀秀

Contact Name of the ethic committee:

Xiuxiu Sun

伦理委员会联系地址:

上海市第六人民医院,上海市徐汇区

Contact Address of the ethic committee:

Shanghai 6th People's hospital ,Shanghai 200233,P. R. China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 2405 6678

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市第六人民医院

Primary sponsor:

Shanghai 6th People's hospital

研究实施负责(组长)单位地址:

上海市第六人民医院,上海市徐汇区

Primary sponsor's address:

Shanghai 6th People's hospital ,Shanghai 200233,P. R. China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院

具体地址:

上海市第六人民医院,上海市徐汇区

Institution
hospital:

Shanghai 6th People's hospital

Address:

Shanghai 6th People's hospital ,Shanghai 200233,P. R. China

经费或物资来源:

江南米道江苏科技有限公司

Source(s) of funding:

Jiangnan Midao Jiangsu Technology Co., Ltd

Target disease:

diabetes mellitus

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究通过随机对照临床试验,探索不同GI大米对2型糖尿病患者血糖控制的影响。  

Objectives of Study:

This study explored the effect of different GI rice on blood glucose control in patients with type 2 diabetes through a randomized controlled clinical trial.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 2型糖尿病诊断明确,糖尿病病程5年内 ② 年龄在18~75岁之间; ③ HbA1c: 7%-9%

Inclusion criteria

① The diagnosis of type 2 diabetes is clear, and the course of diabetes is within 5 years ② Between the ages of 18 and 75; ③ HbA1c: 7% -9%

排除标准:

① 半年内急性心脑血管疾病患者 ② 既往行减重手术; ③ 严重肝、肾功能损害、胃肠道疾病及其他严重器质性疾病; ④ 糖尿病用药需排除胰岛素治疗者及服用α-葡萄糖苷酶抑制剂,SGLT2抑制剂; ⑤ 其他可能影响血糖的药物如:糖皮质激素,噻嗪类利尿剂,β受体阻滞剂等

Exclusion criteria:

① Patients with acute cardiovascular and cerebrovascular diseases within six months ② Previous weight loss surgery; ③ Severe liver and kidney function damage, gastrointestinal diseases, and other serious organic diseases; ④ The medication of diabetes needs to exclude insulin therapists and take insulin α- Glucosidase inhibitors, SGLT2 inhibitors; ⑤ Other drugs that may affect blood sugar, such as glucocorticoids, thiazide diuretics, β Receptor blockers, etc

研究实施时间:

Study execute time:

From 2023-09-01 00:00:00 To 2025-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-28 00:00:00 To 2024-10-31 00:00:00  

干预措施:

Interventions:

组别:

低GI组

样本量:

35

Group:

low GI group

Sample size:

干预措施:

低GI大米,大米GI=55

干预措施代码:

Intervention:

low GI rice, GI=55

Intervention code:

组别:

对照组

样本量:

35

Group:

control group

Sample size:

干预措施:

普通大米,GI=91

干预措施代码:

Intervention:

normal rice,GI=91

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China 

Province:

ShangHai 

City:

 

单位(医院):

上海市第六人民医院 

单位级别:

三甲 

Institution
hospital:

Shanghai 6th People's hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1C

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化白蛋白

指标类型:

次要指标

Outcome:

Glycated albumin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

葡萄糖目标范围内时间

指标类型:

主要指标

Outcome:

TIR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者采用随机数组表发产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers use random array tables to generate random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

两种大米外观相同,受试者及研究者均不知道干预情况。

Blinding:

The appearance of the two types of rice is the same, and neither the subjects nor the researchers are aware of the intervention situation.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

-

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用CRF表进行数据采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-09-28 17:47:20